FDA Investigator: Diane L. Raccasi

- Diane L. Raccasi first started conducting FDA inspections in 2017, with the last inspection in 2019. Over that time, Diane L. Raccasi has conducted 14 inspections at 14 companies across 14 sites.

Documents

FDA 483 Tanvex BioPharma USA, Inc, San Diego | 2019

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 Biocon Limited, Bengaluru | 2019

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 Boehringer Ingelheim Pharma Gmbh & Co Kg, Biberach an der Ris | 2018

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 QOL Medical LLC, Clearwater | 2018

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 Boehringer Ingelheim RCV GmbH & Co KG, Vienna | 2018

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 Alexion Pharma International Operations Unlimited Co., Athlone | 2017

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 Sanofi Genzyme, Cambridge | 2017

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 Rentschler Biotechnologie GmbH, Laupheim | 2017

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 Boehringer Ingelheim Fremont, Inc., Fremont | 2017

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 Wyeth Pharmaceutical, Pearl River | 2017

Out-of-stock
Diane L. Raccasi
Human Drug Form 483

FDA 483 AstraZeneca Pharmaceuticals, LP, Frederick | 2017

Out-of-stock
Diane L. Raccasi
Human Drug Form 483